# Nxera Pharma vs PeptiDream

> Unit: JPY millions (ratios in %)
> Periods: Nxera Pharma = FY ending Dec 2023, consolidated, IFRS / PeptiDream = FY ending Dec 2024, consolidated, IFRS
> Retrieved: 2026-09-30T22:41:18.958Z

| Metric | Nxera Pharma | PeptiDream |
| --- | ---: | ---: |
| Revenue | 12,766 | 46,677 |
| Operating income | — | 21,114 |
| Net income | -7,193 | 15,015 |
| COGS ratio | — | 26.1% |
| Operating margin | — | 45.2% |
| Net margin | -56.3% | 32.2% |
| FCF margin | — | 46.3% |
| Period | FY ending Dec 2023 | FY ending Dec 2024 |
| Source | S100XTYN | S100XRP4 |

## Five-axis industry profile

Each axis shows a rank within that company's primary industry, so peer groups may differ. Missing values are labeled unavailable; no combined score is calculated. Industry rank is not an investment recommendation.

| Axis | Nxera Pharma | PeptiDream |
| --- | ---: | ---: |
| Revenue growth | — | — |
| Profitability | — | 91.7 (6 peers) |
| Cash conversion | — | 62.5 (4 peers) |
| Efficiency | 7.1 (7 peers) | 64.3 (7 peers) |
| Financial strength | — | — |

## Company details

- https://vizora.meequs.com/en/company/nxera-pharma/md
- https://vizora.meequs.com/en/company/peptidream/md

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).